NeuroScientific Biopharmaceuticals Ltd., a health care biotechnology company headquartered in Nedlands, Australia, has been making strides in the pharmaceutical sector with its focus on neurological disorders. The company is dedicated to the development, production, and distribution of peptide-based pharmaceutical products aimed at treating neurological disorders, stroke-related brain injuries, and dementia. These products are exclusively marketed within Australia, reflecting the company’s strategic focus on the domestic market.
As of September 28, 2026, NeuroScientific Biopharmaceuticals Ltd. was listed on the ASX All Markets with a close price of AUD 0.06. The company’s market capitalization stood at AUD 24,160,000, indicating its valuation within the biotechnology sector. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of AUD 0.18 on January 13, 2026, and a 52-week low of AUD 0.055 on August 17, 2026.
The company’s financial metrics reveal a price-to-earnings (P/E) ratio of -4.24, suggesting that it is currently not generating profits. This negative P/E ratio is not uncommon in the biotechnology industry, where companies often invest heavily in research and development before achieving profitability.
NeuroScientific Biopharmaceuticals Ltd. continues to focus on its core mission of addressing unmet medical needs in the field of neurology. By concentrating on innovative peptide-based therapies, the company aims to provide effective treatment options for patients suffering from complex neurological conditions. As it progresses, the company remains committed to advancing its research and expanding its product offerings within the Australian market.
